DarioHealth Q1 Revenue Falls to $5.58M, Net Loss Narrows to $8.25M
DRIO sits 46% above its 52-week low of $5.935 on elevated volume (2.1× avg).
Summary
DarioHealth Corp. reported first-quarter 2026 revenue of $5.58 million, a 17.3% decrease year-over-year, primarily due to the absence of prior-year non-recurring pharmaceutical revenue. Concurrently, the company's net loss attributable to common stockholders narrowed to $8.25 million, an improvement from a $14.07 million loss in Q1 2025, driven by operational efficiencies and reduced expenses. This earnings report follows the company's substantial net loss of $61.7 million for the full year 2025 and recent capital raising efforts, including a $100 million shelf registration and a $20 million at-the-market equity offering in March 2026. While the narrowing loss is a positive sign of cost control, the revenue decline is a significant concern for a growth-oriented company with a small market capitalization and ongoing need for funding. Traders will closely watch future revenue growth, particularly from the B2B segment which now represents 75% of revenues, and the company's path to profitability.
At the time of this announcement, DRIO was trading at $8.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $63.4M. The 52-week trading range was $5.94 to $17.74. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.